Equities analysts forecast that ArQule, Inc. (NASDAQ:ARQL) will announce earnings per share of ($0.06) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for ArQule’s earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.07). ArQule posted earnings of ($0.11) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 45.5%. The business is expected to announce its next quarterly earnings report on Wednesday, May 2nd.
On average, analysts expect that ArQule will report full year earnings of ($0.32) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will post earnings of ($0.35) per share, with EPS estimates ranging from ($0.35) to ($0.34). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for ArQule.
ArQule (NASDAQ:ARQL) last released its earnings results on Monday, March 5th. The biotechnology company reported ($0.09) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09). During the same quarter last year, the firm posted ($0.10) EPS.
ArQule stock traded up $0.44 during trading on Friday, reaching $2.87. 2,456,886 shares of the company’s stock traded hands, compared to its average volume of 371,308. The firm has a market cap of $202.10, a PE ratio of -7.36 and a beta of 1.43. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.98 and a current ratio of 4.98. ArQule has a 52-week low of $0.92 and a 52-week high of $2.94.
Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC acquired a new position in shares of ArQule in the 4th quarter worth approximately $165,000. Virtu Financial LLC grew its stake in shares of ArQule by 343.8% in the 4th quarter. Virtu Financial LLC now owns 129,038 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 99,964 shares during the last quarter. Northern Trust Corp grew its stake in shares of ArQule by 0.9% in the 2nd quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 1,385 shares during the last quarter. Deutsche Bank AG acquired a new position in shares of ArQule in the 4th quarter worth approximately $390,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of ArQule in the 3rd quarter worth approximately $2,220,000. 67.05% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “-$0.06 Earnings Per Share Expected for ArQule, Inc. (NASDAQ:ARQL) This Quarter” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3286322/0-06-earnings-per-share-expected-for-arqule-inc-nasdaqarql-this-quarter.html.
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.